pdr001 antibody Search Results


pdr001  (Palobiofarma)
90
Palobiofarma pdr001
Clinical trials with adenosine pathway inhibitors combined with an immune check inhibitor in cancer
Pdr001, supplied by Palobiofarma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pdr001/product/Palobiofarma
Average 90 stars, based on 1 article reviews
pdr001 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
humanized anti-pd-1 igg4 antibody pdr001  (Novartis)
90
Novartis humanized anti-pd-1 igg4 antibody pdr001
Clinical trials with adenosine pathway inhibitors combined with an immune check inhibitor in cancer
Humanized Anti Pd 1 Igg4 Antibody Pdr001, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/humanized anti-pd-1 igg4 antibody pdr001/product/Novartis
Average 90 stars, based on 1 article reviews
humanized anti-pd-1 igg4 antibody pdr001 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
sabatolimab (mbg453)  (Novartis)
90
Novartis sabatolimab (mbg453)
Clinical trials testing combined targeting of ICRs.
Sabatolimab (Mbg453), supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sabatolimab (mbg453)/product/Novartis
Average 90 stars, based on 1 article reviews
sabatolimab (mbg453) - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
nir178 (a2a antagonist)  (Novartis)
90
Novartis nir178 (a2a antagonist)
Clinical trials evaluating the potential use of purinergic mediators as targets for hepatopancreatobiliary tumors.
Nir178 (A2a Antagonist), supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nir178 (a2a antagonist)/product/Novartis
Average 90 stars, based on 1 article reviews
nir178 (a2a antagonist) - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
tsr-022 antibody  (TESARO Inc)
90
TESARO Inc tsr-022 antibody
The mechanism of immunotherapy regulation based on immune checkpoint <t>pathways</t> <t>(PD-1</t> and PD-L1).
Tsr 022 Antibody, supplied by TESARO Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tsr-022 antibody/product/TESARO Inc
Average 90 stars, based on 1 article reviews
tsr-022 antibody - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
anti-pd1 (pdr001  (AstraZeneca ltd)
90
AstraZeneca ltd anti-pd1 (pdr001
The mechanism of immunotherapy regulation based on immune checkpoint <t>pathways</t> <t>(PD-1</t> and PD-L1).
Anti Pd1 (Pdr001, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-pd1 (pdr001/product/AstraZeneca ltd
Average 90 stars, based on 1 article reviews
anti-pd1 (pdr001 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
spartalizumab pdcd1 pd1 cd279 antibody monoclonal  (ProSci Incorporated)
N/A
Spartalizumab PDCD1 PD1 CD279 Antibody Monoclonal Drug Analogue
   Buy from Supplier
spartalizumab (anti-pd-1)  (Aladdin Scientific Corporation)
N/A
Spartalizumab is a humanized immunoglobulin 4 monoclonal antibody that binds to PD-1 with subanomolar activity and blocks interactions with PD-L1 and PD-L2. Spartalizumab can be used in the study of thyroid undifferentiated carcinoma (ATC).Purity>95% (SDS-PAGE&SEC)Endotoxin
   Buy from Supplier

Image Search Results


Clinical trials with adenosine pathway inhibitors combined with an immune check inhibitor in cancer

Journal: Immune Network

Article Title: Adenosine Blockage in Tumor Microenvironment and Improvement of Cancer Immunotherapy

doi: 10.4110/in.2019.19.e23

Figure Lengend Snippet: Clinical trials with adenosine pathway inhibitors combined with an immune check inhibitor in cancer

Article Snippet: A2AR , PFB509 , Novartis/Palobiofarma , I, Ib , NSCLC , PDR001 (anti-PD-1) , NCT02403193.

Techniques: Clinical Proteomics

Clinical trials testing combined targeting of ICRs.

Journal: Frontiers in Immunology

Article Title: Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors

doi: 10.3389/fimmu.2023.1264327

Figure Lengend Snippet: Clinical trials testing combined targeting of ICRs.

Article Snippet: , Sabatolimab (MBG453) + Spartalizumab (PDR001, anti-PD-1) , Novartis , NCT02608268 , Advanced solid cancers such as melanoma and NSCLC Results: preliminary antitumor activity.

Techniques: Clinical Proteomics, Activity Assay, Biomarker Discovery

Clinical trials evaluating the potential use of purinergic mediators as targets for hepatopancreatobiliary tumors.

Journal: Frontiers in Physiology

Article Title: Purinergic and Adenosinergic Signaling in Pancreatobiliary Diseases

doi: 10.3389/fphys.2022.849258

Figure Lengend Snippet: Clinical trials evaluating the potential use of purinergic mediators as targets for hepatopancreatobiliary tumors.

Article Snippet: CD73 +/− A2AAR , NZV930 (anti-CD73 Ab) +/− PDR001 (anti-PD-1 Ab) +/− NIR178 (A2A antagonist) , Patients with advanced solid tumors including PDAC , NCT03549000 , Phase I/Ib , Novartis Pharmaceuticals.

Techniques: Clinical Proteomics

The mechanism of immunotherapy regulation based on immune checkpoint pathways (PD-1 and PD-L1).

Journal: Acta Pharmaceutica Sinica. B

Article Title: Application of immune checkpoint targets in the anti-tumor novel drugs and traditional Chinese medicine development

doi: 10.1016/j.apsb.2021.03.004

Figure Lengend Snippet: The mechanism of immunotherapy regulation based on immune checkpoint pathways (PD-1 and PD-L1).

Article Snippet: TIM-3 antibodies include TSR-022 from Tesaro for the treatment of advanced or metastatic solid tumors alone or in combination with PD-1 antibody and TSR-022 from Novartis for treatment alone or in combination with PD-1 antibody PDR001 MBG-453 to target advanced malignant tumors currently in clinical trials .

Techniques:

Immune mechanism of TCMs as PD-1/PDL-1 inhibitors.

Journal: Acta Pharmaceutica Sinica. B

Article Title: Application of immune checkpoint targets in the anti-tumor novel drugs and traditional Chinese medicine development

doi: 10.1016/j.apsb.2021.03.004

Figure Lengend Snippet: Immune mechanism of TCMs as PD-1/PDL-1 inhibitors.

Article Snippet: TIM-3 antibodies include TSR-022 from Tesaro for the treatment of advanced or metastatic solid tumors alone or in combination with PD-1 antibody and TSR-022 from Novartis for treatment alone or in combination with PD-1 antibody PDR001 MBG-453 to target advanced malignant tumors currently in clinical trials .

Techniques: Expressing, Cell Culture, Isolation, Transplantation Assay, In Vitro, In Vivo